MKC-Quatsomes: a stable nanovesicle platform for bio-imaging and drug-delivery applications
Guillem Vargas-Nadal, Monica Muñoz-Ubeda, Patricia Alamo, Montserrat Mitjans Arnal, Virtudes Céspedes, Mariana Köber, Elisabet Gonzalez, Lidia Ferrer-Tasies, M Pilar Vinardell, Ramón Mangues, ⁎, Jaume Veciana, ⁎, Nora Ventosa. Nanomedicine
Quatsomes are a new lipid-based nanovesicle platform developed by Nanomol group, that have shown to be highly homogenous and stable in different media for years, important requirements for their use in pharmaceutical products. To facilitate their use in in vivo applications and avoid any potentially toxic side effects, a new Quatsome formulation has been developed, composed of cholesterol and MKC, a surfactant used in many ophthalmic and parenteral formulations on the EU and USA market. In collaboration with several research groups (Biomedical Research Institute Sant Pau and Josep Carreras Research Institute, Hospital de Sant Pau, Barcelona; Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona; and Nanomol Technologies SL), these MKC-Quatsomes were tested in live mice bearing xenografted colorectal tumors. After intravenous injection of fluorescently labelled MKC-Quatsomes, biodistribution assays showed nanovesicle accumulation in tumors, liver, spleen, and kidneys, but not in any other organ. Importantly, no histological alterations or toxicity was found in any of these organs. These new results expand the applicability of quatsomes to further therapeutic or diagnostic approaches that require systemic delivery.
Related Topics: Bioactive materials for therapy and diagnosis